RxDoctor Payments Data

Raiqa Munis, MD

Internal Medicine · Fairfax, VANPI 1245240563

Payments from drug & device makers

$2,372in general payments, 2019–2025

Across 118 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$679
  • Novo Nordisk$376
  • Johnson & Johnson$310
  • Amgen$256
  • Boehringer Ingelheim$244
  • Lilly USA, LLC$182
  • plus $323 from 8 others

What the payments were for

  • Food & beverage$2,35599%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,372 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$102,907
Medicare patients
143
Services billed
915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$84,299
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$39,860
JanuviaSitagliptin Phosphate19$28,252
EliquisApixaban18$23,475
XareltoRivaroxaban18$23,209
MyrbetriqMirabegron26$21,761
RybelsusSemaglutide14$18,667
OzempicSemaglutide13$15,927
TradjentaLinagliptin12$15,898
Synjardy XrEmpagliflozin/Metformin Hcl15$7,585
SynthroidLevothyroxine Sodium27$1,876
Atorvastatin Calcium235$1,804
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,647
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide11$1,194
Levothyroxine Sodium120$1,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$244$107,78182 claims
GSKTrelegy Ellipta$134$39,86030 claims
Novo NordiskRybelsus, Ozempic$376$34,59427 claims
MerckJanuvia$26$28,25219 claims
PfizerEliquis$39$23,47518 claims
Johnson & JohnsonXarelto$310$23,20918 claims
Astellas Pharma US IncMyrbetriq$41$21,76126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →